NCT00005967View on ClinicalTrials.gov

Tipifarnib in Treating Patients With Advanced Hematologic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2000

Primary Completion Date

April 30, 2004

Conditions
Chronic Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
Interventions
DRUG

tipifarnib

Trial Locations (1)

60637-1470

University of Chicago Cancer Research Center, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00005967 - Tipifarnib in Treating Patients With Advanced Hematologic Cancer | Biotech Hunter | Biotech Hunter